Stem cells in animal asthma models: a systematic review

Srour, Nadim; Thébaud, Bernard

doi:10.1016/j.jcyt.2014.08.008

Cited by 19 publications

(27 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSC injection induced a diminution of eosinophils and IL-5, two factors influencing the M2 muscarinic receptor expression [45,46]. In summary, our data suggest that the mechanism of airway hyper-responsiveness decrease by MSC injection was not limited to a modification of inflammation response as observed in numerous studies [47], but was also linked to a modification of airway contractility.…”

Section: Discussionsupporting

confidence: 74%

Mesenchymal Stem Cells Induce Suppressive Macrophages Through Phagocytosis in a Mouse Model of Asthma

et al. 2016

View full text Add to dashboard Cite

Mesenchymal stem cell (MSC) immunosuppressive functions make them attractive candidates for anti-inflammatory therapy in allergic asthma. However, the mechanisms by which they ensure therapeutic effects remain to be elucidated. In an acute mouse model of house dust mite (Der f)-induced asthma, one i.v. MSC injection was sufficient to normalize and stabilize lung function in Der f-sensitized mice as compared to control mice. MSC injection decreased in vivo airway responsiveness and decreased ex vivo carbachol-induced bronchial contraction, maintaining bronchial expression of the inhibitory type 2 muscarinic receptor. To evaluate in vivo MSC survival, MSCs were labeled with PKH26 fluorescent marker prior to i.v. injection, and 1 to 10 days later total lungs were digested to obtain single-cell suspensions. 91.5 6 2.3% and 86.6 6 6.3% of the recovered PKH26 1 lung cells expressed specific macrophage markers in control and Der f mice, respectively, suggesting that macrophages had phagocyted in vivo the injected MSCs. Interestingly, only PKH26 1 macrophages expressed M2 phenotype, while the innate PKH26 2 macrophages expressed M1 phenotype. Finally, the remaining 0.5% PKH26 1 MSCs expressed 10-to 100-fold more COX-2 than before injection, suggesting in vivo MSC phenotype modification. Together, the results of this study indicate that MSCs attenuate asthma by being phagocyted by lung macrophages, which in turn acquire a M2 suppressive phenotype.

show abstract

Section: Discussionsupporting

confidence: 74%

Mesenchymal Stem Cells Induce Suppressive Macrophages Through Phagocytosis in a Mouse Model of Asthma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Preclinical studies demonstrated that MSC could alleviate airway inflammation and airway hyper‐responsiveness in allergic models . The present study provided the initial evidence that the intravenous transplantation of TCs could improve lung inflammation and hyper‐responsiveness in experimental asthma and the combination of TCs with MSCs showed better therapeutic effects on allergen‐induced lung inflammation.…”

Section: Discussionsupporting

confidence: 55%

“…Pathophysiological changes of TCs quantity or function were noticed in a large number of diseases, such as myocardial infarction, heart failure, inflammatory bowel disease, liver fibrosis and systemic sclerosis . Mesenchymal stem cells (MSCs) were found to experimentally alleviate the airway inflammation and decrease airway hyper‐responsiveness and secrete soluble cytokines through paracrine to regulate T cells to treat asthma . Depending on the role of TCs on the immune regulation, we speculate that TCs may play a role in asthma like MSCs.…”

Section: Introductionmentioning

confidence: 96%

Therapeutic roles of telocytes in OVA‐induced acute asthma in mice

Song

Jin

et al. 2017

J Cellular Molecular Medi

View full text Add to dashboard Cite

Telocytes (TCs) newly discovered as the mesenchyme‐derived interstitial cells were found to have supportive effects on mesenchymal stem cells (MSCs). The present study aimed at investigating effects of TCs or TCs gathered with MSCs on experimental airway inflammation and hyper‐responsiveness. The TCs were isolated from the lung tissue of the female BALB/c mice. The ovalbumin (OVA)‐induced asthma model was established. TCs (1 × 106/2 × 106) and/or MSCs (1 × 106) were injected through mice tail vein for consecutive three days before OVA excited the mice. This study at first demonstrated that the transplantation of TCs could improve allergen‐induced asthma by obviously inhibiting airway inflammation and airway hyper‐responsiveness preclinically, with the down‐regulation of Th2‐related cytokine IL‐4, transcription factor GATA‐3 and Th2 cell differentiation, while up‐regulation of Th1‐related cytokine IFN‐γ, transcription factor T‐bet and Th1 cells proliferation in asthma, just like MSCs. Co‐transplantation of TCs with MSCs showed better therapeutic effects on experimental asthma, even though the therapeutic effects of TCs alone were similar to those of MSCs alone. TCs and the combination of TCs with MSCs could improve the airway inflammation and airway hyper‐responsiveness and can be a new alternative for asthma therapy.

show abstract

“…This review uncovered several issues in the reporting of the studies, similar to the issues identified by our systematic review of MSC therapy in animal models of asthma [30]. Numerical data were only exceptionally available, being usually presented graphically, with authors most often not responding to our requests.…”

Section: Discussionmentioning

confidence: 99%

“…However, a prior study by the same group showed that after 90 days, microchimerism was only detectable by PCR, using placenta‐derived amnion and chorion cells with a mesenchymal stem cell‐like phenotype [29], suggesting only a small percentage of MSC‐derived cells survive long term. Furthermore, animal studies of asthma [30] also show a low engraftment proportion.…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal Stromal Cells in Animal Bleomycin Pulmonary Fibrosis Models: A Systematic Review

Srour

Thébaud

2015

Stem Cells Translational Medicine

Self Cite

View full text Add to dashboard Cite

Data from 17 animal studies indicated mesenchymal stromal cell (MSC) therapy led to improvement in bleomycin‐induced lung collagen deposition, pulmonary fibrosis Ashcroft score (in most studies), histopathology, 14‐day survival in animal models, and reduced levels of markers of inflammation. Preclinical data offer better support for human trials of MSCs in acute exacerbations rather than the chronic phase of pulmonary fibrosis.

show abstract

Stem cells in animal asthma models: a systematic review

Cited by 19 publications

References 41 publications

Mesenchymal Stem Cells Induce Suppressive Macrophages Through Phagocytosis in a Mouse Model of Asthma

Mesenchymal Stem Cells Induce Suppressive Macrophages Through Phagocytosis in a Mouse Model of Asthma

Therapeutic roles of telocytes in OVA‐induced acute asthma in mice

Mesenchymal Stromal Cells in Animal Bleomycin Pulmonary Fibrosis Models: A Systematic Review

Contact Info

Product

Resources

About